Cardiovascular Risk Assessment and Disease Management in Patients with Cancer

December 15, 2020 - December 15, 2021


This activity was originally presented at an APP Oncology Summit in 2020. The APP Oncology Summit is a two-day conference designed to provide advanced practice providers (APPs) with the latest evidenced-based strategies to optimize care and outcomes for patients with cancer. This conference is planned with and for advanced practice providers (NPs, PAs, pharmacists, and nurse specialists) and is a collaborative effort of oncology clinicians from multiple organizations in each community. APP Oncology Summit offers a unique opportunity for APPs from various healthcare teams in the community to collaborate, learn from each other and national faculty, and share best practices on a range of issues related to the care of cancer patients.

Target Audience
This activity has been designed to meet the educational needs of oncology nurse practitioners (NPs), physician assistants (PAs), nurse specialists, and other health care providers involved in the management of oncology patients.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe short-term and delayed cardiotoxic effects of newer cancer treatments
  • Explain strategies for screening and monitoring of patient with cancer for cardiovascular toxicity before, during and after cancer treatment
  • Outline a multidisciplinary approach to managing cardiovascular risk in patients with cancer using current guideline recommendations to optimize survivorship outcomes

Activity Launch Date - 12/15/2020
Expiration Date - 12/15/2021

Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome comments about how to better serve your needs.

Copyright Information
Copyright © 2020 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.


Time Description
58 min

Cardiovascular Risk Assessment and Disease Management in Patients with Cancer

10 min

Final Evaluation

Faculty & Disclosures

Faculty & Disclosures


Daniel Addison, MD
Assistant Professor of Internal Medicine
Co-Director-Cardiology Program
Ohio State University Wexner Medical Center
Columbus, OH

Faculty Bio

Dr. Daniel Addison is currently an Assistant Professor of Medicine at The Ohio State University in Columbus, Ohio.

He obtained his medical degree at Meharry Medical College, and completed his internal medicine residency and cardiology fellowship at the Baylor College of Medicine in Houston, TX, before completing an NIH T32 Advanced Cardiovascular Imaging fellowship at the Massachusetts General Hospital, where he focused on Cardio-Oncology.

Since joining the academic faculty as a physician-scientist at Ohio State in 2017, he has helped accelerate the growth of the Cardio-Oncology Program, of which is currently co-Director.

His research interests include cardio-oncology, health equity, and advanced multimodality cardiac imaging. His research in cardio-oncology has already received multiple awards, and he is currently supported by a k-award from the National Cancer Institute. He has also been involved both in the clinical and education realms of the field, serving as a cardiac imager, and a faculty leader of the cardiology fellowship Research Committee. He also is a member of OSU’s Cancer Control, and Cancer Survivorship Teams, assisting in the cross disciplinary development of cardio-oncology patient centered clinical and research strategies.

Faculty Disclosure Statement
Daniel Addison discloses no relevant financial relationships with any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients during the past 12 months.

Planning Committee & Non-faculty Contributors

  • Beth Faiman has served as a Consultant for Celgene and Karyopharm.
  • Dr. Joslyn Rudoni has served on Advisory Boards for Abbvie and AstraZeneca.
  • Dr. Marc Earl has served on Advisory Boards for Merck, Coherus, Genentech, and Bristol-Myers Squibb.

All other nonfaculty contributors involved in the planning, development, and editing or review of the content disclosed no relevant financial relationships with any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients during the past 12 months.

Learner Assurance Statement
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.

CE Information

Launch Date/Expiration Date
This activity was launched on December 15, 2020 and will expire on December 15, 2021.


Accreditation Statement
Horizon CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How To Claim Credit

  • There are no fees to participate in the activity.
  • Participants must review all activity information, including the learning objectives, disclosure statements, and content.
  • To receive CME credit, participants must complete the activity and the post-activity evaluation.
  • Certificates can be printed immediately.

Any questions? Please check out our FAQs section or feel free to contact us.